FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.415,79 +584,50 (+0,99%)
23andMe Holding Co. (ME)
Dopo ore:
| Chiusura precedente | 0,4590 |
| Aperto | 0,4550 |
| Denaro | 0,4628 x 2200 |
| Lettera | 0,5915 x 200 |
| Min-Max giorno | 0,4502 - 0,4780 |
| Intervallo di 52 settimane | 0,3500 - 2,2100 |
| Volume | |
| Media Volume | 7.544.898 |
| Capitalizzazione | 224,122M |
| Beta (5 anni mensile) | 1,28 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,1100 |
| Prossima data utili | 26 mag 2024 - 30 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,23 |
GlobeNewswire23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignanciesSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meet
- GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disease is common About one in 13 African Americans have the sickle cell trait. Many are unaware that they are carriers or what it means to be a carrier of the sickle cell trait SOUTH SAN FRANCISCO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human gen
- GlobeNewswire
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these additional variants occur more often in people of African American and Hispanic/Latino descent 23andMe also granted an FDA Predetermined Change Control Plan, allowing the company to update its BRCA report with additional variants without a pre-market submission, provided those variants meet the same rigor
